Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Source MDx form molecular medicine partnership

Pfizer and Source MDx form molecular medicine partnership

28th December 2007

Pfizer and Source MDx have formed a multi-year partnership in which both companies will collaborate to develop and validate transitional molecular medicines.

In particular, the two companies will work on the development of RNA-based pharmacodynamic and predictive biomarkers within Pfizer’s cancer and inflammation therapeutic programmes.

The collaboration is hoped to bring together Pfizer’s expertise in genomic profiling and Source MDx’s experience in RNA transcription profiling to identify biomarkers in whole blood and circulating rare cells.

Under the agreement, Source MDx and Pfizer will work together on a selection of clinical studies in oncology and inflammation.

Dr Danute Bankaitis-Davis, executive vice-president of Source MDx, welcomed the development collaboration and confirmed that the partnership was the result of a long-standing close relationship between the two companies.

“We believe this collaboration will provide many benefits to Pfizer’s drug development programmes and further add to Source MDx’s industry leadership in the development of RNA transcript-based biomarkers,” he stated.

Source MDx and Pfizer have worked together since 2002, collaborating in over 20 pre-clinical and clinical projects applying RNA transcription profiling.

Earlier this month, Pfizer and Adolor announced a worldwide collaboration to develop and commercialise the compounds ADL5859 and ADL5747 for the treatment of pain.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.